Davies Mary-Ann, Kassanjee Reshma, Rosseau Petro, Morden Erna, Johnson Leigh, Solomon Wesley, Hsiao Nei-Yuan, Hussey Hannah, Meintjes Graeme, Paleker Masudah, Jacobs Theuns, Raubenheimer Peter, Heekes Alexa, Dane Pierre, Bam Jamy-Lee, Smith Mariette, Preiser Wolfgang, Pienaar David, Mendelson Marc, Naude Jonathan, Schrueder Neshaad, Mnguni Ayanda, Roux Sue Le, Murie Katie, Prozesky Hans, Mahomed Hassan, Rossouw Liezel, Wasserman Sean, Maughan Deborah, Boloko Linda, Smith Barry, Taljaard Jantjie, Symons Greg, Ntusi Ntobeko, Parker Arifa, Wolter Nicole, Jassat Waasila, Cohen Cheryl, Lessells Richard, Wilkinson Robert J, Arendse Juanita, Kariem Saadiq, Moodley Melvin, Vallabhjee Krish, Wolmarans Milani, Cloete Keith, Boulle Andrew
Health Intelligence, Western Cape Government: Health, South Africa.
Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, South Africa.
medRxiv. 2022 Jan 12:2022.01.12.22269148. doi: 10.1101/2022.01.12.22269148.
We aimed to compare COVID-19 outcomes in the Omicron-driven fourth wave with prior waves in the Western Cape, the contribution of undiagnosed prior infection to differences in outcomes in a context of high seroprevalence due to prior infection, and whether protection against severe disease conferred by prior infection and/or vaccination was maintained.
In this cohort study, we included public sector patients aged ≥20 years with a laboratory confirmed COVID-19 diagnosis between 14 November-11 December 2021 (wave four) and equivalent prior wave periods. We compared the risk between waves of the following outcomes using Cox regression: death, severe hospitalization or death and any hospitalization or death (all ≤14 days after diagnosis) adjusted for age, sex, comorbidities, geography, vaccination and prior infection.
We included 5,144 patients from wave four and 11,609 from prior waves. Risk of all outcomes was lower in wave four compared to the Delta-driven wave three (adjusted Hazard Ratio (aHR) [95% confidence interval (CI)] for death 0.27 [0.19; 0.38]. Risk reduction was lower when adjusting for vaccination and prior diagnosed infection (aHR:0.41, 95% CI: 0.29; 0.59) and reduced further when accounting for unascertained prior infections (aHR: 0.72). Vaccine protection was maintained in wave four (aHR for outcome of death: 0.24; 95% CI: 0.10; 0.58).
In the Omicron-driven wave, severe COVID-19 outcomes were reduced mostly due to protection conferred by prior infection and/or vaccination, but intrinsically reduced virulence may account for an approximately 25% reduced risk of severe hospitalization or death compared to Delta.
我们旨在比较西开普省由奥密克戎毒株引发的第四波新冠疫情与之前几波疫情的结果,探讨在既往感染导致血清阳性率较高的情况下,未诊断出的既往感染对结果差异的影响,以及既往感染和/或疫苗接种所提供的针对重症疾病的保护是否得以维持。
在这项队列研究中,我们纳入了2021年11月14日至12月11日(第四波)期间实验室确诊为新冠的20岁及以上公共部门患者,以及之前几波疫情的同期患者。我们使用Cox回归比较了各波疫情中以下结果的风险:死亡、重症住院或死亡以及任何住院或死亡(均在诊断后≤14天),并对年龄、性别、合并症、地理位置、疫苗接种和既往感染进行了调整。
我们纳入了第四波疫情中的5144名患者和之前几波疫情中的11609名患者。与由德尔塔毒株引发的第三波疫情相比,第四波疫情中所有结果的风险均较低(死亡的调整风险比[aHR][95%置信区间(CI)]为0.27[0.19;0.38])。在调整疫苗接种和既往诊断感染后,风险降低幅度较小(aHR:0.41,95%CI:0.29;0.59),而在考虑未确定的既往感染后,风险进一步降低(aHR:0.72)。第四波疫情中疫苗的保护作用得以维持(死亡结果的aHR:0.24;95%CI:0.10;0.58)。
在由奥密克戎毒株引发的疫情波次中,新冠重症结果的减少主要归因于既往感染和/或疫苗接种所提供的保护,但与德尔塔毒株相比固有毒力降低可能导致重症住院或死亡风险降低约25%。